title: Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
abstract: Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines. This present article describes the severity classification and the pharmacological treatment of stable COPD. GesEPOC identifies four clinical phenotypes with differential treatment: non-exacerbator, mixed COPD-asthma, exacerbator with emphysema and exacerbator with chronic bronchitis. Pharmacological treatment of COPD is based on bronchodilation in addition to other drugs depending on the clinical phenotype and severity. Severity is established by the BODE/BODEx multidimensional scales. Severity can also be approximated by assessing airflow obstruction, dyspnea, level of physical activity and history of exacerbations. GesEPOC is a new, more individualized approach to COPD treatment according to the clinical characteristics of the patients.
authors.affiliation: Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, España. marcm@separ.es
authors.forename: Marc
authors.initials: M
authors.lastname: Miravitlles
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Soler-Cataluña
authors.forename: Myriam
authors.initials: M
authors.lastname: Calle
authors.forename: Jesús
authors.initials: J
authors.lastname: Molina
authors.forename: Pere
authors.initials: P
authors.lastname: Almagro
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Quintano
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Riesco
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Trigueros
authors.forename: Pascual
authors.initials: P
authors.lastname: Piñera
authors.forename: Adolfo
authors.initials: A
authors.lastname: Simón
authors.forename: José Luis
authors.initials: JL
authors.lastname: López-Campos
authors.forename: Joan B
authors.initials: JB
authors.lastname: Soriano
authors.forename: Julio
authors.initials: J
authors.lastname: Ancochea
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000631:Aminopyridines / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000453:epidemiology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D015897:Comorbidity; D003521:Cyclopropanes / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D010641:Phenotype; D029424:Pulmonary Disease, Chronic Obstructive / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology; D011656:Pulmonary Emphysema / Q000188:drug therapy / Q000453:epidemiology; D019141:Respiratory System Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013030:Spain; D013806:Theophylline / Q000008:administration & dosage / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D005100:Expectorants; D019141:Respiratory System Agents; D000515:alpha 1-Antitrypsin; C424423:Roflumilast; D013806:Theophylline